Groundbreaking oral cancer pill enters human testing
NCT ID NCT06717750
Summary
This is the first human study of an experimental oral medication called CSCJC3456 for people with advanced solid tumors that have stopped responding to standard treatments. The trial aims to find safe doses and see how the drug behaves in the body, while also checking if it can shrink tumors. It will enroll about 102 adults with various advanced cancers, including liver, colorectal, gastric, and endometrial cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110001, China
Contact
Conditions
Explore the condition pages connected to this study.